CG Invites 
Welcome,         Profile    Billing    Logout  
 6 Products   6 Diseases   6 Products   995 Trials   3123 News 


«12...4041424344454647484950...5253»
  • ||||||||||  oxaliplatin / Generic mfg., AiRuiKa (camrelizumab) / Incyte, capecitabine / Generic mfg.
    [VIRTUAL] Changes in immune function and prognosis in advanced perihilar cholangiocarcinoma patients treated with immunotherapy combined with different topical therapies (On-Demand) -  Jul 21, 2020 - Abstract #ESMO2020ESMO_424;    
    Cohort A: 125I particle stent + HAI + camrelizumab; Cohort B: 125I particle stent + camrelizumab; Cohort C: HAI + camrelizumab...HAI plan: HAI consisted of infusions of oxaliplatin 40 mg/ m2 for 2 hours, followed by 5-fluorouracil 800 mg/m2 for 22 hours on days 1∼3 every 3 weeks, a maximum of 6 cycles of HAI are applied for tumor control patients followed by maintenance with oral capecitabine until tumor progression...Secondary endpoints includes progress free survival (PFS), near-term outcome indicators (TBIL/DBIL/AST/ALT/ CEA/CA199 etc.), long-term outcome indicators (stent patency rate/ tumour response rate etc.), complications (fever/ bleeding/pain etc.), changes in immune-inflammatory cytokines (TNF-α/IL-1β/IL-6/ IL-8/CD4/CD8/IgA/IgG/IgM/complement C3 and C4), etc. Legal entity responsible for the study: The authors. Funding: Has not received any funding.
  • ||||||||||  AiRuiKa (camrelizumab) / HLB Bio Group
    Trial initiation date, Real-world evidence:  RFA Plus Carrizumab vs Carrizumab Alone for HCC (clinicaltrials.gov) -  Jul 7, 2020   
    P2,  N=120, Recruiting, 
    Camrelizumab showed antitumour activity in pretreated Chinese patients with advanced hepatocellular carcinoma, with manageable toxicities, and might represent a new treatment option for these patients. Initiation date: Jan 2020 --> Aug 2020
  • ||||||||||  AiRuiKa (camrelizumab) / HLB Bio Group
    Trial completion date, Trial initiation date, Trial primary completion date:  Carbon-Ion Radiotherapy Plus Camrelizumab for Locally Recurrent Nasopharyngeal Carcinoma (clinicaltrials.gov) -  Jul 7, 2020   
    P2/3,  N=180, Not yet recruiting, 
    Initiation date: Jan 2020 --> Aug 2020 Trial completion date: May 2025 --> Sep 2025 | Initiation date: May 2020 --> Sep 2020 | Trial primary completion date: May 2024 --> Sep 2024
  • ||||||||||  AiRuiKa (camrelizumab) / HLB Bio Group
    Trial completion date, Trial primary completion date:  Study of PD-1 Inhibitor Combination With Autologous Cell Immunotherapy in the Metastatic Renal Cell Carcinoma (clinicaltrials.gov) -  Jul 7, 2020   
    P2,  N=90, Recruiting, 
    Immunotherapy was well tolerated generally and had manageable side effects, which is worth of popularization and application in clinical practice. Trial completion date: Jun 2021 --> Jun 2022 | Trial primary completion date: Jun 2021 --> Jun 2022
  • ||||||||||  AiRuiKa (camrelizumab) / HLB Bio Group, famitinib (SHR 1020) / Jiangsu Hengrui Pharma
    Enrollment open:  Study to Evaluate the Efficacy and Safety of Camrelizumab and Famitinib in Patients With Advanced Solid Tumor (clinicaltrials.gov) -  Jul 1, 2020   
    P2,  N=205, Recruiting, 
    Camrelizumab administration combined with MWA was safe in the treatment of advanced NSCLC, and the combination improved the ORR of camrelizumab alone compared to previous reports. Not yet recruiting --> Recruiting
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
    Review, Journal:  Emerging agents and regimens for hepatocellular carcinoma. (Pubmed Central) -  Jun 28, 2020   
    The combination of an anti-PD-1 antibody and an anti-angiogenesis agent has shown more potent anti-tumor effects in early phase clinical trials and is now the hotspot in clinical studies. Furthermore, these agents are investigated in combination treatment with surgery or other loco-regional therapies in patients with early or intermediate-stage HCC.
  • ||||||||||  AiRuiKa (camrelizumab) / HLB Bio Group
    Enrollment closed:  SHR-1210 in Patients With Relapsed or Refractory Extranodal NK/T Cell Lymphoma (clinicaltrials.gov) -  Jun 17, 2020   
    P2,  N=97, Active, not recruiting, 
    Recruiting --> Active, not recruiting | Trial completion date: Mar 2020 --> Dec 2020 | Trial primary completion date: Sep 2019 --> Jun 2020 Not yet recruiting --> Active, not recruiting
  • ||||||||||  AiRuiKa (camrelizumab) / HLB Bio Group
    Trial completion, Trial completion date, Trial primary completion date, PD(L)-1 Biomarker, IO biomarker:  A Study of SHR-1210 in Combination With Pemetrexed and Carboplatin in Subjects With Non-squamous NSCLC (clinicaltrials.gov) -  Jun 9, 2020   
    P3,  N=419, Completed, 
    Recruiting --> Active, not recruiting Recruiting --> Completed | Trial completion date: Dec 2019 --> Aug 2019 | Trial primary completion date: Dec 2018 --> Jul 2019
  • ||||||||||  luxeptinib (CG-806) / Aptose Biosci
    Trial completion date, Trial primary completion date:  A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas (clinicaltrials.gov) -  Jun 4, 2020   
    P1,  N=130, Recruiting, 
    Decitabine plus camrelizumab may reverse resistance to PD-1 inhibitors in patients with relapsed/refractory cHL. Trial completion date: Dec 2020 --> May 2022 | Trial primary completion date: Nov 2020 --> Dec 2021